An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease. - Wikidata - awgldk - TriplyDB

An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease.

An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease.

http://www.wikidata.org/entity/Q34364368

about

Revolutionizing Alzheimer's disease and clinical trials through biomarkers The Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers Efficacy and Safety of MMFS-01, a Synapse Density Enhancer, for Treating Cognitive Impairment in Older Adults: A Randomized, Double-Blind, Placebo-Controlled Trial.Introducing Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, an open access journal of the Alzheimer's Association Endpoints in preclinical Alzheimer's disease trials.Memory, executive, and multidomain subtle cognitive impairment: clinical and biomarker findings.Endpoints for Pre-Dementia AD Trials: A Report from the EU/US/CTAD Task Force.Establishing Composite Cognitive Endpoints for Use in Preclinical Alzheimer's Disease Trials.A Summary Score for the Framingham Heart Study Neuropsychological Battery.Highly sensitive measurements of disease progression in rare disorders: Developing and validating a multimodal model of retinal degeneration in Stargardt disease CAP--advancing the evaluation of preclinical Alzheimer disease treatments.Influence of amyloid and APOE on cognitive performance in a late middle-aged cohort.Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: Introducing the Z-scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score.Glycemic control, cognitive function, and family support among middle-aged and older Hispanics with diabetes: The Hispanic Community Health Study/Study of Latinos Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward.Outcomes Assessment in Clinical Trials of Alzheimer's Disease and its Precursors: Readying for Short-term and Long-term Clinical Trial Needs.Prevention Trials in Alzheimer's Disease: Current Status and Future Perspectives.Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer's Disease Dementia.Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β.Prevention studies in Alzheimer's disease: progress towards the development of new therapeutics.Detectable Neuropsychological Differences in Early Preclinical Alzheimer's Disease: A Meta-Analysis.Optimal composite scores for longitudinal clinical trials under the linear mixed effects model.The Essentials of a Global Index for Cognitive Function.Power analysis to detect treatment effects in longitudinal clinical trials for Alzheimer's disease.A composite measure of cognitive and functional progression in Alzheimer's disease: Design of the Capturing Changes in Cognition study.Design of pilot studies to inform the construction of composite outcome measures.Statistical properties of continuous composite scales and implications for drug development.Study partners should be required in preclinical Alzheimer's disease trials.EU/US/CTAD Task Force: Lessons Learned from Recent and Current Alzheimer's Prevention Trials.Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: The PACC5.Cognitive changes in prodromal Parkinson's disease: A review.Neural and behavioral substrates of disorientation in mild cognitive impairment and Alzheimer's disease.Clinical Trials for Disease-Modifying Therapies in Alzheimer's Disease: A Primer, Lessons Learned, and a Blueprint for the Future.Measuring cognition and function in the preclinical stage of Alzheimer's disease.Cognitive composite score association with Alzheimer's disease plaque and tangle pathology

P2860

Q26744882-85885FEE-9CC2-4D18-A20A-2D0621B0CD08 Q26849380-7B050F0C-62D4-459E-9358-5F8EE9AF5F72 Q27333870-7C684FAB-2B90-475B-97FD-352348D8FA06 Q30489394-4225D954-1BDB-49E5-A99A-6D1A805E3AFB Q35694848-B6107441-8474-4668-8919-F8005D807806 Q35889053-FC2E303E-B045-421E-95C6-530ED658BA28 Q35910923-3E374B03-7BE0-4607-8BF4-20FE3DCB2D9B Q35939801-57AF407F-A6C2-4FB5-AC74-A60C9847D3EF Q36154820-2A4D2BBB-EE2F-4365-9164-9DF077F2B529 Q36326882-82352246-40EE-41AF-90BC-DC4C60EF809F Q36843004-65932A44-2BC3-4BBC-8584-7903F5739676 Q36850584-3276F4F8-A6D9-4139-84B6-35279E4AA68B Q36934154-94C83B62-D218-4B72-BB98-1E078A97B67A Q37031336-9405BCF3-7A9F-4B09-9AD1-EF44F8A91009 Q37670673-123F513B-233B-4723-9BE3-FDA2FF38312C Q37730520-92E5B017-96E6-413B-81FB-0F49186E6986 Q38719665-4FDB3115-A4B6-459C-8C67-E20AC7FAE228 Q38808542-DFBAEF23-38E7-4355-B4B6-12C976E64045 Q38933111-599D0029-0A2C-45D9-A33B-39FD83ED17FB Q38983318-0340E6AB-0E2D-46CD-B67B-54E69306F2F9 Q39301541-B9474AE8-D37B-4CD7-ADB5-86C326505E3A Q40680870-F572A159-7660-4895-A6CF-D66F3BEEAE2A Q41111155-91E7CD2D-BD31-436E-924B-0650E33567F5 Q41502500-8E18E8AD-4856-4E9A-820F-09DC7BE91EFD Q42656112-E24521EF-4126-4ACD-A94F-4CE794A7DBB7 Q42691219-CB73BF05-BA05-4B41-AA1E-ADE335BF1D6A Q44656052-9E4F7399-AAA7-431A-A335-172F62F8D751 Q46028917-9B9E3F9D-4BC4-453D-B0BE-555B75E6F98A Q46211759-3BE03675-84B2-4A2C-9CF5-93F97245F277 Q47141681-1F5CA8FC-93A2-4F62-9757-EAEEC6A99DD4 Q47860019-8ACAB924-511F-4AA6-B720-1795E579B17D Q55017686-C0313B24-8B66-429E-8659-35FBAEF94301 Q55364364-6AE32CDC-BB22-447F-A6CA-8A13D3C95A7F Q55442237-E0052462-6797-40E4-8751-6A13961A697A Q58751300-E53855FD-15DF-4FF1-AC42-42B08C6A58C0

P2860

An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease.

http://www.wikidata.org/entity/Q34364368

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

An empirically derived composi ...... eclinical Alzheimer's disease.

@ast

An empirically derived composi ...... eclinical Alzheimer's disease.

@en

An empirically derived composi ...... eclinical Alzheimer's disease.

@nl

type

label

An empirically derived composi ...... eclinical Alzheimer's disease.

@ast

An empirically derived composi ...... eclinical Alzheimer's disease.

@en

An empirically derived composi ...... eclinical Alzheimer's disease.

@nl

prefLabel

An empirically derived composi ...... eclinical Alzheimer's disease.

@ast

An empirically derived composi ...... eclinical Alzheimer's disease.

@en

An empirically derived composi ...... eclinical Alzheimer's disease.

@nl

P1433

Q34364368-CF770CF9-0B79-4D18-B98B-EFB7B10C3E9A

P1476

Q34364368-4E985CF8-AB05-485F-B56E-E8AC10604F39

P2093

Q34364368-11A0B510-F969-4004-86CD-ABFC7679FC2C

Q34364368-12301A93-5DA1-4662-9CD1-2650C64B2704

Q34364368-3C588E08-0117-4B28-A788-37FE9E2D07B1

Q34364368-65EED771-CDE6-4E33-906B-8BEBFB753CDB

Q34364368-AD3F6C17-8B54-47A0-88E1-645913347178

Q34364368-BE36A349-C992-47C7-A27C-111B6F4E30F1

P2860

Q34364368-00438ABF-B21F-4EDB-BCF3-04B80615202B

Q34364368-041EAD41-BD41-4EE9-8D91-704D897F175B

Q34364368-0887BA2D-A1B9-48C4-82A0-B29011787C40

Q34364368-0B462130-CC04-445A-B206-58EBF6D40950

Q34364368-13811988-CBA6-4F2E-B107-C302C7D77706

Q34364368-1654E3D4-480E-4F39-871F-66FC55556B70

Q34364368-17389293-DB19-4250-98D6-1B5768E6A1D3

Q34364368-17479FBB-7601-42A3-A301-51C9E33244C4

Q34364368-18A52C8C-B20D-4C3E-8E5D-948126E80D9A

Q34364368-1AAFEA8F-EEBF-4E43-AA37-039692B3BF09

P304

Q34364368-4E6B25CC-0689-4CE5-9038-2E442EABFC10

P31

Q34364368-D46E066B-6383-43DC-8DAA-B502918C408C

P356

Q34364368-FDB56ACE-DD7E-464D-80D3-B084F99F8CC3

P433

Q34364368-3FD1D167-5552-442E-A57C-9B6175325122

P478

Q34364368-9323BAF8-ECE4-4CB5-8B43-07B2BC57F554

P50

Q34364368-AD79CFCA-E882-43A2-BAE1-1372DD530EE0

Q34364368-C2BE7749-EEB1-4D97-A0D6-8E91B61332AF

Q34364368-DA625BB5-D983-48C7-8854-5745A906D552

Q34364368-FC72AFF9-8761-46F6-9CED-1DA84F172E51

P577

Q34364368-32520E95-67BB-45A8-A436-530811D59726

P698

Q34364368-97B7B6CD-2572-4B9A-80C3-96EB3662CDA2

P921

Q34364368-813FDF2E-BE55-4A4C-A5E9-EFDBB36DACC9

P932

Q34364368-ADCEC81B-D2F2-4204-9638-D98B14A475D7

P356

J.JALZ.2014.02.002

P1433

Alzheimer's and Dementia

P1476

An empirically derived composi ...... eclinical Alzheimer's disease.

@en

P2093

Adam S Fleisher

http://www.w3.org/2001/XMLSchema#string

Jessica B Langbaum

http://www.w3.org/2001/XMLSchema#string

Lisa L Barnes

http://www.w3.org/2001/XMLSchema#string

Napatkamon Ayutyanont

http://www.w3.org/2001/XMLSchema#string

Pierre N Tariot

http://www.w3.org/2001/XMLSchema#string

Suzanne B Hendrix

http://www.w3.org/2001/XMLSchema#string

P2860

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

The Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers

Ushering in the study and treatment of preclinical Alzheimer disease

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

The Minority Aging Research Study: ongoing efforts to obtain brain donation in African Americans without dementia

Ginkgo biloba for prevention of dementia: a randomized controlled trial.

Latent structure and factorial invariance of a neuropsychological test battery for the study of preclinical Alzheimer's disease.

Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI)

Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial.

The neuropathology of probable Alzheimer disease and mild cognitive impairment.

P304

666-674

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JALZ.2014.02.002

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

David A Bennett

P577

2014-04-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24751827

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

4201904

http://www.w3.org/2001/XMLSchema#string